Albumin-free factor VIII formulations
An albumin-free Factor VIII formulation comprising: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent.
1. A Factor VIII composition formulated without adding albumin to said composition and comprising the following formulation excipients in addition to Factor VIII:
4% (w/v) to 10% (w/v) of a bulking agent, wherein said bulking agent is mannitol; 1% (w/v) to 4% (w/v) of a stabilizing agent selected from the group consisting of sucrose, trehalose, and raffinose;
1 mM to 5 mM calcium salt;
100 mM to 300 mM NaCl; and
a buffering agent for maintaining a pH of approximately between 6 and 8.
2. The Factor VIII composition of claim 1 , wherein said bulking agent is present in an amount of about 8% (w/v).
3. The Factor VIII composition of claim 1 , wherein said stabilizing agent is present in an amount of about 2% (w/v).
4. The Factor VIII composition of claim 1 , wherein said stabilizing agent is sucrose.
5. The Factor VIII composition of claim 1 , wherein said stabilizing agent is trehalose.
6. The Factor VIII composition of claim 1 , wherein said calcium salt is calcium chloride.
7. The Factor VIII composition of claim 1 , wherein said NaCl is present in an amount of from 150 mM to 250 mM.
8. The Factor VIII composition of claim 1 , wherein said NaCl is present in an amount of about 225 mM.
9. The Factor VIII composition of claim 1 , wherein said calcium salt is present in an amount of from 1 mM to 5 mM.
10. The Factor VIII composition of claim 1 , wherein said composition is in lyophilized form.
11. The Factor VIII composition of claim 1 , wherein said buffering agent comprises between about 10 mM and about 50 mM histidine.
12. The Factor VIII composition of claim 11 , wherein the histidine is present in an amount of about 25 mM.
13. The Factor VIII composition of claim 1 , wherein said buffering agent comprises a member selected from the group consisting of tris-(hydroxymethyl)-aminomethane, 1,3-bis-[tris-(hydroxy-methyl)methylamino]-propane, piperazine-N,N′-bis-(2-ethanesulfonic acid), 3-(N-morpholino) propanesulfonic acid, N-2-hydroxyethyl-piperazine-N′-2-ethanesulthnic acid, 2-(N-morpholino) ethane-sulfonic acid and N-2-acetamido-2-aminoethanesulfonic acid.
14. The Factor VIII composition of claim 11 , wherein said buffering agent further comprises a member selected from the group consisting of tris(hydroxymethyl)-aminomethane, 1,3-bis-[tris-(hydroxy-methyl)methylamino]-propane, piperazine-N,N′-bis-(2-ethanesulfonic acid), 3-(N-morpholino) propanesulfonic acid, N-2-hydroxyethyl-piperazine-N′-2-ethanesulfonic acid, 2-(N-morpholino) ethane-sulfonic acid and N-2-acetamido-2-aminoethanesulfonic acid.
15. The Factor VIII composition of claim 14 , wherein said buffering agent further comprises tris-(hydroxymethyl)-aminomethane.
16. The Factor VIII composition of claim 15 , wherein the tris-(hydroxymethyl)-aminomethane is present in an amount of about 20 mM.
17. The Factor VIII composition of claim 1 , further comprising a surfactant.
18. The Factor VIII composition of claim 17 , Wherein the surfactant is present in an amount of about 0.03% (w/v).
19. The Factor VIII composition of claim 17 , wherein said surfactant is selected from the group consisting of polyoxyethylene (20) sorbitan fatty acid ester, polyoxyethylene (80) sorbitan fatty acid ester, polyoxyalkylene ether, and polyoxyethylene 35 lauryl ether.
20. The Factor VIII composition of claim 19 , where said surfactant is polyoxyethylene (80) sorbitan fatty acid ester and is present in an amount of between 0.02% (w/v) and 0.1% (w/v).
21. The Factor VIII composition of claim 1 , further comprising an antioxidant.
22. The Factor VIII composition of claim 21 , wherein said antioxidant is glutathione.
23. The Factor VII composition of claim 22 , wherein said glutathione is present in an amount of between 0.05 mg/ml and 1.0 mg/ml.
24. The Factor VIII composition of claim 1 in combination with a diluent.
25. The Factor VIII composition of claim 1 in combination with 2 ml of diluent.
26. The Factor VIII composition of claim 1 in combination with 5 ml of diluent.
27. A Factor VIII composition formulated without adding albumin to said composition and comprising the following formulation excipients in addition to Factor VIII:
2% (w/v) to 6% (w/v) hydroxyethyl starch;
1% (w/v) to 4% (w/v) of a stabilizing agent selected from the group consisting of sucrose, trehalose, and raffinose;
1 mM to 5 mM calcium salt;
100 mM to 300 mM NaCl; and
a buffering agent for maintaining a pH of approximately between 6 and 8, wherein said buffering agent comprises between about 10 mM and about 50 mM histidine.
28. The Factor VIII composition of claim 27 , wherein said hydroxyethyl starch is present in an amount of about 4%.
29. The Factor VIII composition of claim 27 , wherein said NaCl is present in an amount of about 200 mM.
30. The Factor VIII composition of claim 27 , wherein said stabilizing agent is present in an amount of about 2% (w/v).
31. An improved method of lyophilizing an aqueous pharmaceutical formulation comprising
a crystallizable bulking agent, a stabilizing agent, a calcium salt, and NaCl, wherein said method comprises the steps of:
(a) freezing the aqueous pharmaceutical formulation at a temperature of less than about 35° C.,
(b) annealing the pharmaceutical formulation at between about −30° C. and −19° C.;
(c) lowering the temperature of the pharmaceutical formulation to between −45° C. and 55° C.;
(d) annealing the pharmaceutical formulation at between about −30° C. and −39° C.; and
(e) freeze-drying the pharmaceutical formulation.
32. The method of claim 31 , wherein the temperature in step (c) is less than −50° C.
33. The method of claim 31 , wherein said pharmaceutical formulation further comprises Factor VIII.
34. The method of claim 31 , wherein said pharmaceutical formulation further comprises a buffering agent.
35. The method of claim 34 , wherein said buffering agent comprises histidine.
36. The method of claim 34 , wherein said buffering agent comprises tris-(hydroxymethyl)-aminomethane.
37. The method of claim 31 , wherein said bulking agent is mannitol.
38. The method of claim 31 , wherein said stabilizing agent is trehalose.
39. The method of claim 31 , wherein said calcium salt is calcium chloride.